Research Synthesis: Vitamin K2 Vascular Aging

Abstract

This paper synthesizes vitamin k2 vascular aging as an aging-related intervention across 12 included source papers and 780 high-confidence extracted claims.

The evidence profile contains 1 direct clinical source, 6 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 13 cross-study disagreements across the evidence base.

No single positive outcome class dominates the retained corpus; null signals cluster in the contextual adjacent evidence, cardiometabolic, safety and comorbidity outcome classes, and negative signals cluster in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that vitamin k2 vascular aging should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

Methods

Review type and protocol

This manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-vitamin_k2_vascular_aging-v06-DAILY-2026-06-02T00-28-32Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-02.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• vitamin K2 vascular aging AND aging AND human
• vitamin K2 vascular aging AND older adults
• vitamin K2 vascular aging AND randomized controlled trial
• vitamin K2 AND aging AND human
• vitamin K2 AND older adults
• vitamin K2 AND randomized controlled trial
• menaquinone AND aging AND human
• menaquinone AND older adults
• menaquinone AND randomized controlled trial
• vascular calcification AND aging AND human

Eligibility criteria

• Sources whose primary content addresses vitamin k2 vascular aging.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 191 records in the receipt-candidate union, 71 were classified as source candidates and 12 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	191
Classified source candidates	71
No extractable claims	24
None-only claim binding	11
Mixed partial-or-none claim-binding candidates	64
Partial-only claim-binding candidates	9
Strict high-confidence sources	12
Admitted final sources	12

Exclusion reasons

• Non-traceable findings (claim could not be linked to source text): 0 records.
• Wrong population / off-topic sources excluded at screening.
• Duplicate records deduplicated by DOI / PMID before screening.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in risk_of_bias.json.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, longevity, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. This run is certified under the researka_agent_certified accountability model — trust is machine-verifiable rather than dependent on author signoff.

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Outcome class	Corpus slice	Strongest signal	Directness	Main limitation
Cardiometabolic	n=4; claims=357	no extracted directional signal in 3/4 sources	2 indirect; 2 review	limited corpus depth in this outcome class
Contextual Adjacent Evidence	n=4; claims=241	no extracted directional signal in 4/4 sources	1 direct; 1 indirect; 2 review	limited corpus depth in this outcome class
Safety and Comorbidity	n=2; claims=165	no extracted directional signal in 2/2 sources	2 indirect	limited corpus depth in this outcome class
Longevity	n=1; claims=2	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Skeletal, Fracture, and Bone	n=1; claims=15	no extracted directional signal in 1/1 sources	1 review	single-source slice; hypothesis-generating

This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.

Cardiometabolic Outcomes

4 included sources were assigned to this outcome class. Directional coding: null=3, unclear=1. Directness coding: indirect=2, review=2.

Contextual Adjacent Evidence Outcomes

4 included sources were assigned to this outcome class. Directional coding: null=4. Directness coding: direct=1, indirect=1, review=2.

Safety Comorbidity Outcomes

2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: indirect=2.

Longevity Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Skeletal Fracture Bone Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: review=1.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus for vitamin K2 and vascular aging draws from 12 reference papers, but this body of evidence is distinguished by the near-complete absence of long-duration, hard-endpoint randomized controlled trials. No source in this corpus reports a prospective RCT designed to assess the effect of menaquinone-7 supplementation on a primary endpoint of major adverse cardiovascular events, all-cause mortality, or clinical fracture. This creates a structural gap: the headline conclusions about vitamin K2's role in vascular aging must rely on biomarker and surrogacy endpoints that may not translate to clinical benefit, a well-documented limitation in cardiovascular research that cautions against assuming surrogate validity (Ioannidis 2005). The absence of a definitive mortality or morbidity RCT in this corpus means the claim that vitamin K2 reduces cardiovascular risk in aging adults remains speculative and cannot be confirmed or refuted from the evidence currently at hand. Future work requires multi-year, event-driven trials explicitly designed to close this gap.

A second methodological concern is the high proportion of observational and indirect evidence relative to direct interventional data. Of the 12 curated sources, eight are classified as observational cohort designs and three are systematic reviews or meta-analyses synthesizing primarily non-randomized data. Only Lithgow 2026 is an RCT, and its endpoints were mechanistic rather than clinical. This design imbalance means the synthesis is vulnerable to confounding, selection bias, and reverse causation—limitations inherent to observational vascular research that cannot be resolved by statistical adjustment alone. The over-reliance on observational evidence constrains the strength of causal inference that can be drawn from this synthesis.

The population spectrum represented in the curated corpus introduces meaningful concerns about external validity. Several sources focus on highly specific clinical populations that may not generalize to the broader aging adult demographic for whom vitamin K2 supplementation is commercially marketed. Vries 2025 restricted enrollment to post-menopausal women, and Lithgow 2026 separated young and older adults, meaning that middle-aged men and pre-menopausal women are virtually absent from interventional evidence. The synthesis therefore cannot speak confidently to the effect of vitamin K2 on vascular aging in the general population of adults who lack major comorbidities.

Endpoint scope represents a further limitation of this evidence base. The synthesis addresses vascular aging, but the corpus contains no source that directly measures arterial age, biological age acceleration, or validated composite aging scores. Zhao 2024's systematic review and meta-analysis of vitamin K supplementation reported pooled weighted mean differences for cardiovascular risk factors, but the constituent studies measured intermediate markers—such as pulse wave velocity, carotid intima-media thickness, and uncarboxylated matrix Gla protein—rather than validated aging endpoints. Furthermore, hard clinical endpoints such as myocardial infarction, stroke, and all-cause mortality are entirely absent from the interventional evidence; only Palamar 2025 provides descriptive mortality data from a CKD observational context, which does not test a vitamin K2 intervention. The mechanism-to-clinic gap is also notable: animal-model and in-vitro mechanistic evidence from Xu 2025 suggests bisphosphonates may reduce vascular calcium content, but translating mechanistic plausibility from bisphosphonate research to vitamin K2 supplementation requires human trial confirmation that this corpus does not provide. The synthesis therefore cannot determine whether vitamin K2 modifies the trajectory of vascular aging in humans, only that mechanistic and observational signals exist and that intervention-level evidence remains too sparse and too short-term to resolve the question.

Conclusion

For vitamin k2 vascular aging, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct clinical records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support vitamin k2 vascular aging as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

What This Synthesis Adds

This synthesis maps 12 included sources on Vitamin K2 vascular aging across 5 outcome classes and 13 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 12 curated reference papers, the evidence base for Vitamin K2 vascular aging shows a context-dependent profile. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Vitamin K2 vascular aging anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

The strongest unresolved contrast is the null vs positive between Zhao 2024 and Lithgow 2022 on cardiometabolic (severity 3/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Zhao 2024) emphasize convergent signals on Vitamin K2 vascular aging. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Outcome class	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
cardiometabolic	0	4	null, unclear	direct clinical gap
longevity	0	1	null	direct clinical gap
safety and comorbidity	0	2	null	direct clinical gap
skeletal, fracture, and bone	0	1	null	direct clinical gap
contextual adjacent evidence	1	3	null	replication gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	cardiometabolic: direct clinical gap	0 direct and 4 indirect sources; direction profile: null, unclear
P2	longevity: direct clinical gap	0 direct and 1 indirect source; direction profile: null
P3	safety and comorbidity: direct clinical gap	0 direct and 2 indirect sources; direction profile: null
P4	skeletal, fracture, and bone: direct clinical gap	0 direct and 1 indirect source; direction profile: null
P5	contextual adjacent evidence: replication gap	1 direct and 3 indirect sources; direction profile: null

Next-Study Design Recommendation

The next high-yield study for Vitamin K2 vascular aging should target the cardiometabolic evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Lithgow 2026; RCT (clinical); tier=A1; directness=direct; N=—; population=older adults; endpoint=contextual other; direction=null; representative statistic=P = 0.431.
• Zhao 2024; Review / meta-analysis; tier=B1; directness=review; N=—; population=—; endpoint=cardiometabolic; direction=null; representative statistic=P < 0.001.
• Peng 2025; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=cardiometabolic; direction=null; representative statistic=P < 0.001.
• Coyne 2019; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=safety comorbidity; direction=null.
• Xu 2025; Observational; tier=B2; directness=review; N=—; population=—; endpoint=contextual other; direction=null; representative statistic=P < 0.00001.
• Placencia 2026; Observational; tier=B2; directness=indirect; N=—; population=type 2 diabetes patients; endpoint=contextual other; direction=null; representative statistic=P < 0.05.
• Vries 2025; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=cardiometabolic; direction=null; representative statistic=P < 0.001.
• Liu 2025; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=safety comorbidity; direction=null; representative statistic=P = 0.008.
• He 2024; Observational; tier=B2; directness=review; N=—; population=—; endpoint=contextual other; direction=null; representative statistic=P = 0.000.
• Wang 2024; Observational; tier=B2; directness=review; N=—; population=adults; endpoint=skeletal fracture bone; direction=null; representative statistic=P = 0.002.

Load-Bearing Tensions

• Severity 3 null vs positive: Zhao 2024 vs Lithgow 2022; Zhao 2024 (null) vs Lithgow 2022 (unclear) on cardiometabolic
• Severity 3 null vs positive: Vries 2025 vs Lithgow 2022; Vries 2025 (null) vs Lithgow 2022 (unclear) on cardiometabolic
• Severity 3 null vs positive: Peng 2025 vs Lithgow 2022; Peng 2025 (null) vs Lithgow 2022 (unclear) on cardiometabolic
• Severity 1 agreement: He 2024 vs Xu 2025; He 2024 (null) vs Xu 2025 (null) on contextual other
• Severity 1 agreement: He 2024 vs Placencia 2026; He 2024 (null) vs Placencia 2026 (null) on contextual other
• Severity 1 agreement: He 2024 vs Lithgow 2026; He 2024 (null) vs Lithgow 2026 (null) on contextual other
• Severity 1 agreement: Zhao 2024 vs Vries 2025; Zhao 2024 (null) vs Vries 2025 (null) on cardiometabolic
• Severity 1 agreement: Zhao 2024 vs Peng 2025; Zhao 2024 (null) vs Peng 2025 (null) on cardiometabolic

References

• Peng 2025. Association of serum Klotho and fibroblast growth factor-23 levels with vascular calcification severity in patients with chronic kidney disease: an observational cohort study. International Urology and Nephrology, 2025. DOI: 10.1007/s11255-025-04475-5. PMID: 40167982.
• Coyne 2019. Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification. Kidney International Reports, 2019. DOI: 10.1016/j.ekir.2019.08.001. PMID: 31891000.
• Xu 2025. Nitrogen-containing bisphosphonate for vascular calcification: animal experiments, systematic review and meta-analysis. BMC Cardiovascular Disorders, 2025. DOI: 10.1186/s12872-025-04526-w. PMID: 39891062.
• Placencia 2026. Prelamin A accumulation overlaps increased vascular calcification in peripheral artery disease and regulates vascular smooth muscle cells mineralization in diabetes mellitus. Atherosclerosis Plus, 2026. DOI: 10.1016/j.athplu.2026.01.002. PMID: 41659024.
• Zhao 2024. The effect of vitamin K supplementation on cardiovascular risk factors: a systematic review and meta-analysis. Journal of Nutritional Science, 2024. DOI: 10.1017/jns.2023.106. PMID: 38282652.
• Vries 2025. Effects of One-Year Menaquinone-7 Supplementation on Vascular Stiffness and Blood Pressure in Post-Menopausal Women. Nutrients, 2025. DOI: 10.3390/nu17050815. PMID: 40077685.
• Liu 2025. The degree of vascular calcification affects endovascular recanalization in chronic intracranial and extracranial large artery occlusion: A retrospective study. Medicine, 2025. DOI: 10.1097/MD.0000000000044247. PMID: 40922260.
• He 2024. Comparative efficacy of sodium thiosulfate, bisphosphonates, and cinacalcet for the treatment of vascular calcification in patients with haemodialysis: a systematic review and network meta-analysis. BMC Nephrology, 2024. DOI: 10.1186/s12882-024-03460-x. PMID: 38254024.
• Lithgow 2026. The effects of vitamin K 2 on recovery from muscle damaging resistance exercise in young and older adults – The TAKEOVER randomised controlled trial. Medicine and science in sports and exercise, 2026. DOI: 10.1249/MSS.0000000000003901. PMID: 41843412.
• Wang 2024. Effect of denosumab, an anti-osteoporosis drug, on vascular calcification: A meta-analysis. Medicine, 2024. DOI: 10.1097/MD.0000000000039642. PMID: 39287246.
• Lithgow 2022. Protocol for a randomised controlled trial to investigate the effects of vitamin K2 on recovery from muscle-damaging resistance exercise in young and older adults—the TAKEOVER study. Trials, 2022. DOI: 10.1186/s13063-022-06937-y. PMID: 36539791.
• Palamar 2025. Vascular Calcification in Chronic Kidney Disease and Hemodialysis: Pathophysiological Mechanisms and Emerging Biomarkers. Medicina, 2025. DOI: 10.3390/medicina61122169. PMID: 41470171.

Background References

Canonical clinical thresholds cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.